METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Clinical trials for METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Custom-Made vaccine targets tough cancers in early trial
⭐️ VACCINE ⭐️ Recruiting nowThis early-phase study is testing a personalized vaccine made from a patient's own tumor cells and blood. The goal is to see if it's safe and possible to create and give this vaccine to people with advanced pancreatic or colorectal cancer that has spread. About 300 adults with th…
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: ⭐️ VACCINE ⭐️
Last updated May 20, 2026 11:53 UTC
-
New drug cocktails target Hard-to-Treat gut cancers
Disease control Recruiting nowThis study is testing several new experimental drugs called RAS(ON) inhibitors, alone or with standard chemotherapy, in people with advanced colorectal or pancreatic cancer that has spread. About 1,130 adults will participate to see if these combinations are safe and can shrink t…
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated May 26, 2026 09:52 UTC
-
New combo aims to outsmart pancreatic Cancer's defenses
Disease control Recruiting nowThis study tests a new drug called ONT01 combined with standard chemotherapy (gemcitabine and nab-paclitaxel) for people with metastatic pancreatic cancer that has worsened after initial treatment. The goal is to see if ONT01 can reprogram immune cells in the tumor to make the ch…
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated May 26, 2026 09:35 UTC
-
New drug combo aims to boost chemo for tough pancreatic cancer
Disease control Recruiting nowThis early-phase trial tests whether adding an experimental MK2 inhibitor (zunsemetinib) to standard chemotherapy (mFOLFIRINOX) can work better for people with metastatic pancreatic cancer that hasn't been treated yet. About 51 adults will join to find the safest dose and watch f…
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated May 22, 2026 13:55 UTC
-
Could a stem cell boost help fight hard-to-treat cancers?
Disease control Recruiting nowThis early-stage trial is testing a new treatment for people with metastatic pancreatic or breast cancer that has spread. The treatment combines chemotherapy drugs with high-dose vitamin C and the patient's own stem cells to try to overcome drug resistance. The main goal is to ch…
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: General Oncology, Inc. • Aim: Disease control
Last updated May 22, 2026 13:53 UTC
-
New drug targets Hard-to-Treat KRAS cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called BBO-11818 in people with advanced solid tumors (lung, pancreatic, colorectal, or others) that have a specific KRAS gene mutation. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Abo…
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) • Aim: Disease control
Last updated May 20, 2026 11:58 UTC
-
New hope for pancreatic cancer: drug combo targets tumors and blood clots
Disease control Recruiting nowThis study tests a new drug called pegcetacoplan combined with standard chemotherapy (mFOLFIRINOX) in people with pancreatic cancer that has spread to other parts of the body. The goal is to see if the combination is safe and helps control the cancer better, while also reducing d…
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated May 20, 2026 11:57 UTC
-
Promising new drug combo takes on deadly pancreatic cancer in major trial
Disease control Recruiting nowThis study tests whether a new drug combination (TQB2868 injection plus anlotinib capsules) with chemotherapy can help people with metastatic pancreatic cancer live longer compared to standard chemotherapy alone. About 566 adults aged 18-75 with stage IV pancreatic cancer will ta…
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New MRI scan could predict pancreatic cancer treatment success
Diagnosis Recruiting nowThis study tests a special MRI scan that uses an experimental contrast agent called hyperpolarized carbon-13 pyruvate. Unlike standard MRI, this scan shows how tumors process nutrients, which may help doctors predict whether pancreatic cancer treatments are working. The study inv…
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Sponsor: University of California, San Francisco • Aim: Diagnosis
Last updated May 26, 2026 09:52 UTC
-
New drug aims to fight deadly wasting in pancreatic cancer patients
Symptom relief Recruiting nowThis study tests a drug called ponsegromab combined with standard chemotherapy to see if it helps adults with advanced pancreatic cancer who are losing weight and appetite (cachexia). About 982 participants will receive either ponsegromab or a placebo alongside their first chemot…
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: Pfizer • Aim: Symptom relief
Last updated May 20, 2026 11:54 UTC
-
Blood test may speed up treatment decisions for pancreatic cancer patients
Knowledge-focused Recruiting nowThis study looks at whether a simple blood test that measures tumor DNA (ctDNA) can tell doctors within weeks if chemotherapy is shrinking a patient's pancreatic cancer. Currently, doctors wait about 8 weeks for a scan to see if treatment is working. The goal is to see if the blo…
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: University of Miami • Aim: Knowledge-focused
Last updated May 26, 2026 09:51 UTC
-
New study aims to unlock pancreatic Cancer's weaknesses
Knowledge-focused Recruiting nowThis study is for people with pancreatic cancer that can be removed by surgery or has spread. Researchers want to see how different drugs change tumor biology by comparing biopsies taken before and after treatment. The goal is not to cure the disease now, but to learn which drugs…
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Phase: EARLY_PHASE1 • Sponsor: OHSU Knight Cancer Institute • Aim: Knowledge-focused
Last updated May 22, 2026 13:52 UTC
-
New drug OMO-103 studied in pancreatic cancer patients to reveal tumor changes
Knowledge-focused Recruiting nowThis early phase 1 trial is studying how the drug OMO-103 affects pancreatic cancer cells in 12 patients with advanced or metastatic disease. The main goal is to see if the drug causes measurable changes in the tumor's biology by comparing tissue samples taken before and after tr…
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Phase: EARLY_PHASE1 • Sponsor: OHSU Knight Cancer Institute • Aim: Knowledge-focused
Last updated May 18, 2026 12:10 UTC